Frequently asked Questions
Here you´ll find answers to frequently asked questions about the biotech company BRAIN AG. If you have further questions, do not hesitate to contact us: email@example.com.
When and where was BRAIN AG founded?
BRAIN AG has been founded in 1993 in Darmstadt, Germany.
When and where was BRAIN AG listed?
BRAIN AG is listed in the Prime Standard of the Frankfurt Stock Exchange since February 9th, 2016. (BNN; ISIN DE0005203947 / WKN 520394)
Why do you have registered shares?
Under the German Stock Corporation Act (Aktiengesetz), shares in a company are either in registered or in bearer form. Both forms of shares are prevalent in Germany and well established. Registered shares facilitate a better communication between the company and its stockholders and lead to improved transparency in regards to the company’s ownership structure.
What is BRAIN AG’s vision and mission?
Mission is what an organization is or does. Our Mission: creating breakthrough bio-based products and solutions for nutrition, health and the environment.
Vision is what an organization desires to become. Our Vision: we are the White Biotech Specialists in finding and exploring high-value niches in our products business and novel solutions in our science business. We are much more agile than others and always look to produce products in-house or with partners.
What are BRAIN AG’s main products and services?
BRAIN AG solely focusses on the business-to-business (B2B) segment in industrial biotechnology. On this BRAIN AG has two main segments: BioScience and BioIndustrial. BioScience: this segment contains our taylor-made-solution services, our libraries and our R&D activities. BioIndustrial: this segment inlcudes our production companies with a focus on enzymes, microorganisms and bioactive natural compounds.
In addition, BRAIN AG owns about 46% in Solascure Ltd., which is focused on advanced wound debridement therapies. The company is at-equity consolidated.
What is industrial biotechnology?
Industrial biotechnology contributes to more sustainable industrial processes and products. BRAIN AG improves industrial processes and develops new products and services by applying science at the cellular, molecular and genomic level.
Which companies build the BRAIN Group?
- Companies in our BioScience segment which contains our taylor-made-solutions, libraries and own R&D activities: BRAIN AG, BRAIN LLC, AnalytiCon Discovery GmbH, AnalytiCon Discovery LLC.
- Companies in our BioIndustrial segment which contains our production companies: Biocatalysts Ltd., Biocatalysts Inc., WeissBioTech GmbH, L.A. Schmitt GmbH.
- SolasCure Ltd.: for advanced wound care solutions; a 45.81% at-equity consolidation.
Why is BRAIN AG an important contributor to the bioeconomy?
Brain is a market leader and trendsetter in the bioeconomy (bio-based economy). The concept of Bioeconomy involves the use of biotechnology in the production of bio-based products. Our products and solutions directly address these United Nations´ SDGs: 2, 3, 6, 9, 12 and 13.
What are "enzymes", "microorganisms" and "bioactive natural compounds"?
Enzymes are proteins, which are often industrially produced from microbes. Enzymes catalyze specific biochemical reactions. Microorganisms (or microbes) are living organisms, existing in single-celled form or in cell-colony form; for example, bacteria or fungi. They are industrially produced via fermentation. Bioactive natural compounds ("bioactives") are present in small quantities e.g. in foods like fruits, vegetables, and whole grains, and provide health benefits beyond the basic nutritional value.
What exactly is your BioArchive?
The BioArchive is our proprietary "nature´s toolbox": it is essentially an exclusive library of edible biomaterials, genes, habitats, metagenomes, microorganisms, plant fractions as well as natural and naturally inspired compounds. The BioArchive has a high value for BRAIN AG and its stakeholders with around 140 patents granted, 60 patent families and more than 450 person-years to reproduce this library. The BioArchive powers our taylor-made-solution services, the new business development and our product sales. Due to our ready to screen libraries, we can steer our R&D effort more efficiently and shorten the development cycles to market launch.
Are you planning to grow organically or through acquisitions?
Organic growth remains the primary driver of our strategy. We will continue to invest in our own product development and technological innovations, improving the speed, number of projects and innovations brought to market. In addition and for the time being, we currently focus on bolt-on acquisitions to add to our product offerings and improve economies of scale. By doing so, we will strive to best support our customers’ needs and to create value for our stakeholders.
Where can I find information on the BRAIN management?
Please have a look at the website section Management.
Can you explain BRAIN AG’s commitment to sustainability?
Please visit our website section ESG Investor Information.
How is your fiscal year defined?
BRAIN AG’s fiscal year deviates from the calendar year. Our fiscal year starts on October 1st and ends on September 30th of the following year.
Where can I find the most recent financial update?
Please find BRAIN´s financial publications here.
Which accounting standard does BRAIN Group use?
BRAIN Group deploys IFRS, International Financial Reporting Standards for its financial market communication.